PerkinElmer
check quantity

CD276 (human) AlphaLISA Detection Kit, 100 assay points

The AlphaLISA® immunoassay kit for human CD276 enables the quantitative determination of human Cluster of Differentiation 276 (CD276, B7-H3) in serum, buffered solution, and cell culture media using a homogeneous AlphaLISA assay (no wash steps).

For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).

Part Number
Unit Size
List Price
Your Price
Quantity
AL3060HV
100 Assay Points
893.00 USD
 
more
AL3060C
500 Assay Points
2144.00 USD
 
more
AL3060F
5,000 Assay Points
17200.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

Formats:

  • Our 100 assay point kit allows you to run 100 wells in 96-well format, using a 100 µL reaction volume (10 µL of sample).
  • Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).
  • Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).

Features:

  • No-wash steps, no separation steps
  • ELISA alternative technology
  • Sensitive detection
  • Broad sample compatibility
  • Small sample volume
  • Results in less than 3 hours
  • Half the time of an ELISA assay

AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

CD276 (Cluster of Differentiation 276, or B7-H3) is a type I transmembrane protein belonging to the B7 family of co-stimulatory proteins (e.g., B7-1, or CD80). It signals through CD28 family molecules such as CD28 and CTLA4. It is expressed ubiquitously, such as dendritic cells derived from monocytes, epithelial cells of sinonasal tissue, extravillous trophoblast cells and Hofbauer cells of the placenta. It is an immune checkpoint molecule, involved in the regulation of T-cell-mediated immune response. It is expressed by some solid tumours, as a biomarker for detection of neuroblastoma cells and is the target of anticancer therapy.

Specifications

Assay Target CD276
Assay Target Class Protein
Automation Compatible Yes
Detection Method Alpha
Product Brand Name AlphaLISA
Shipping Condition Blue Ice
Therapeutic Area Cancer
Unit Size 100 Assay Points
Resources, Events & More
  • All

Application Note

Effects of 5FU and Sorafenib on Proliferation and Biomarker Expression in a Colorectal Cancer Model Using AlphaLISA and EnSight Solutions

A variety of chemotherapeutic drugs with different modes of action have been developed and tested as potential therapies for colorectal cancer. Characterizing the effects of potential drugs with different modes of action is a key part of the process.

In this application note you will learn:

  • How to rapidly measure multiple biomarkers in both cell culture supernatant and lysates from the same wells of a microplate to examine complex protein expression profiles from a colorectal cancer cellular model
  • Benefits of using AlphaLISA® technology for characterizing the effects of potential drugs with different modes of action on a cell culture model of human colorectal cancer
  • How to measure the effects of drug treatments, such as 5FU and Sorafenib, on cellular proliferation by automated well-imaging and cell counting using the EnSight® multimode plate reader
  • Examples of the data and analysis you can generate for such biomarker and proliferation assays

PDF 3 MB
Quantifying Changes in CD28 and CTLA-4 Levels in Peripheral Blood Mononuclear Cells with AlphaLISA Technology

One approach to immunotherapy is the modulation of immune checkpoints that are critical in regulating the degree and duration of immune system responses and preventing autoimmunity.

In this application note, you will learn:

  • Why AlphaLISA® technology is an effective assay for the detection and quantification of biomarkers such as CD28 and CTLA-4
  • How to run an AlphaLISA assay to detect and quantify immuno-oncology biomarkers
  • Benefits of using Alpha technology for biomarker quantification assays
  • An example of the data and analysis you can generate for biomarker assays

PDF 1 MB

Brochure

Flyer

Manual

Manual: AlphaLISA CD276 Detection Kit AL3060

Protocol for performing an AlphaLISA human CD276 detection and quantitation assay

PDF 615 KB